Innospec (NASDAQ:IOSP) insider Philip Curran sold 2,000 shares of Innospec stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $73.63, for a total transaction of $147,260.00. Following the completion of the transaction, the insider now directly owns 4,218 shares in the company, valued at approximately $310,571.34. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Philip Curran also recently made the following trade(s):
- On Wednesday, March 7th, Philip Curran sold 1,268 shares of Innospec stock. The stock was sold at an average price of $68.24, for a total transaction of $86,528.32.
Shares of Innospec stock opened at $75.60 on Friday. The company has a current ratio of 2.13, a quick ratio of 1.28 and a debt-to-equity ratio of 0.24. Innospec has a 52-week low of $74.05 and a 52-week high of $75.05. The company has a market capitalization of $1.83 billion, a PE ratio of 16.12 and a beta of 1.03.
The business also recently announced a semiannual dividend, which will be paid on Thursday, May 31st. Shareholders of record on Monday, May 21st will be given a dividend of $0.44 per share. This represents a yield of 1.18%. The ex-dividend date of this dividend is Friday, May 18th. This is an increase from Innospec’s previous semiannual dividend of $0.39. Innospec’s payout ratio is currently 16.74%.
IOSP has been the topic of a number of analyst reports. BidaskClub downgraded shares of Innospec from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. Zacks Investment Research downgraded shares of Innospec from a “hold” rating to a “strong sell” rating in a research report on Friday, February 23rd. ValuEngine raised shares of Innospec from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Finally, Johnson Rice raised shares of Innospec from an “accumulate” rating to a “buy” rating in a research report on Tuesday, April 24th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $70.50.
Large investors have recently added to or reduced their stakes in the business. C M Bidwell & Associates Ltd. purchased a new stake in Innospec during the 4th quarter worth approximately $142,000. UBS Group AG grew its position in Innospec by 69.3% during the 1st quarter. UBS Group AG now owns 2,771 shares of the specialty chemicals company’s stock worth $190,000 after purchasing an additional 1,134 shares during the last quarter. Xact Kapitalforvaltning AB purchased a new stake in Innospec during the 4th quarter worth approximately $222,000. Boston Private Wealth LLC purchased a new stake in Innospec during the 1st quarter worth approximately $220,000. Finally, Amalgamated Bank purchased a new stake in Innospec during the 4th quarter worth approximately $245,000. 89.35% of the stock is currently owned by institutional investors.
Innospec Company Profile
Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals for use as fuel additives, ingredients for personal care, home care, agrochemical, mining and other applications, and oilfield chemicals worldwide. It operates through four segments: Fuel Specialties, Performance Chemicals, Oilfield Services, and Octane Additives.
Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.